StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Sign in to jot down a private note about VERU. Only you ever see it.
External sites have their own terms, paywalls, and accuracy standards. Stonvex doesn't endorse the content there.
Three bull points, three bear points, and one “what would change my mind” line — both sides forced onto one screen as a research note rather than a tip sheet.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q2 2025 2025-06-30 | Q1 2025 2025-03-31 | Annual 2024 2024-09-30 | Q2 2024 2024-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $16.89M | $10.23M |
Operating Income | $-25.92M | $-18.37M | $-36.17M | $-26.83M |
Net Income | $-24.18M | $-16.85M | $-37.80M | $-29.27M |
EPS (Diluted) | $-1.65 | $-1.15 | $-2.80 | $-2.23 |
Total Assets | $27.33M | $32.67M | $60.42M | $64.63M |
Total Liabilities | $11.99M | $11.62M | $28.10M | $27.01M |
Cash & Equivalents | $15.01M | $20.02M | $24.92M | $29.15M |
Free Cash Flow OCF − CapEx | $-24.55M | $-19.07M | $-21.84M | $-17.41M |
Shares Outstanding | 14.65M | 146.58M | 14.64M | 146.38M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.